XIRP2

Across TCGA pan-cancer cohorts, XIRP2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated XIRP2 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher XIRP2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated XIRP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, ESCA, and UCEC are the cancer types where XIRP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.664	0.371	.003	26	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.807	0.295	.013	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
READ	DFS	Median	All	1.000	0.499	.023	8	view →
COAD	OS	Median	II,III,IV	0.236	0.672	.008	8	view →
STAD	DFS	Median	III,IV	0.711	0.298	.025	4	view →
BLCA	OS	Median	IV	0.763	0.557	.026	4	view →
KIRC	DFS	Median	All	0.625	0.882	.005	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
PRAD	DFS	Median	All	0.826	0.935	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

XIRP2–LUAD (DFS)

Open the LUAD breakdown →